IKBKE and acute myeloid leukemia: Compared to normal HSPCs, AML cells appear to rely more heavily upon TBK1/IKKε; this TBK1/IKKε addiction plausibly provides a selective therapeutic opportunity for AML patients via pharmacologic inhibition of TBK1/IKKε [18, 231].